Review Article

The Current State of Targeted Agents in Rectal Cancer

Table 4

Clinical trials of cetuximab in preoperative treatment of rectal cancer.

AuthorPhaseStudy design(regimen)NRT dose (Gy)pCR rateDiarrhea (≥ G 3)Reference

KuoI5FU+ cetuximab2050.42/17(12%)2/20(10%)[67]
BertoliniICaplri + cetuximab2050.45/20(25%)2/10(20%)[68]
VelenikI/IICapecitabine + cetuximab40452/40(5%)6/40(15%)[69]
HorisbergerI/IICAPOX + cetuximab4850.44/48(8%)9/48(19%)[70]
ChangIICetuximab then 5FU + cetux4050.43/40(7.5%)3/40(7.5%)[71]
RodelIICapecitabine + cetuximab37453/37(8.1%)4/37(11%)[72]
Oncofacts.comIICaplri + cetuximab5050.44/50(8%)15/50(30%)[44]

RT:Radiotherapy, pCR: Pathological complete response.